Global Cardioselective Beta Blockers Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Cardioselective Beta Blockers Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Cardioselective beta blockers intercept the activation of beta-1 adrenergic receptors present at the nerve endings of the sympathetic nervous system. This eventually results in diminished activity of the heart, such as a reduction in systolic pressure, heart rate and cardiac contractility. Cardioselective agents have a better affinity for β1-adrenergic receptors located in the heart, whereas nonselective agents work on β1-adrenergic receptors and β2-adrenergic receptors located in bronchial musculature.
Cardioselective Beta Blockers report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Cardioselective Beta Blockers market is projected to reach US$ 9461 million in 2029, increasing from US$ 6251 million in 2022, with the CAGR of 6.1% during the period of 2024 to 2029. Demand from Hospitals and Specialty Clinics are the major drivers for the industry.
Widespread Demand for Metoprolol for Cardiovascular DiseasesTreatment of Cardiovascular Diseases with Metoprolol presents a huge revenue opportunity for companies in the market. The metoprolol segment holds the dominant market share in pharmaceuticals in 2022. Outstanding safety and efficacy, ease of administration, and affordability are key factors for the widespread utilization of this class of drugs in the treatment of heart failure and hypertension. Surging demand for metoprolol over the past few years is likely to drive the market in the near future.
Development of drug delivery technologies to improve the safety and efficacy of cardioselective beta-blockersOngoing research into the mechanism of action of beta-blockers enables the company to develop drugs with unique pharmacological profiles. This may facilitate the off-label use of beta-blockers and provide new business opportunities for drug manufacturers in the near future. In addition, pharmaceutical companies are working to develop beta-blockers with improved routes of administration to reduce their common side effects and enhance the targeting of these drugs in the treatment of angina, cardiac arrhythmias, and chronic heart failure.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Cardioselective Beta Blockers market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
F. Hoffmann-La Roche Ltd
Fresenius Kabi AG
Pfizer Inc
Bayer AG
GSK Plc
Sanofi
Novartis AG
Mylan N.V
Teva Pharmaceutical Industries Ltd
Zydus Group
Viatris Inc
Merck & Co., Inc
Recordati S.p.A
Pierre Fabre Group
AbbVie, Inc
AstraZeneca
Segment by Type
Oral
Injection
Hospitals
Specialty Clinics
Other
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Cardioselective Beta Blockers market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Cardioselective Beta Blockers, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Cardioselective Beta Blockers industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Cardioselective Beta Blockers in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Cardioselective Beta Blockers introduction, etc. Cardioselective Beta Blockers Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Cardioselective Beta Blockers market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Cardioselective Beta Blockers report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Cardioselective Beta Blockers market is projected to reach US$ 9461 million in 2029, increasing from US$ 6251 million in 2022, with the CAGR of 6.1% during the period of 2024 to 2029. Demand from Hospitals and Specialty Clinics are the major drivers for the industry.
Widespread Demand for Metoprolol for Cardiovascular DiseasesTreatment of Cardiovascular Diseases with Metoprolol presents a huge revenue opportunity for companies in the market. The metoprolol segment holds the dominant market share in pharmaceuticals in 2022. Outstanding safety and efficacy, ease of administration, and affordability are key factors for the widespread utilization of this class of drugs in the treatment of heart failure and hypertension. Surging demand for metoprolol over the past few years is likely to drive the market in the near future.
Development of drug delivery technologies to improve the safety and efficacy of cardioselective beta-blockersOngoing research into the mechanism of action of beta-blockers enables the company to develop drugs with unique pharmacological profiles. This may facilitate the off-label use of beta-blockers and provide new business opportunities for drug manufacturers in the near future. In addition, pharmaceutical companies are working to develop beta-blockers with improved routes of administration to reduce their common side effects and enhance the targeting of these drugs in the treatment of angina, cardiac arrhythmias, and chronic heart failure.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Cardioselective Beta Blockers market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
F. Hoffmann-La Roche Ltd
Fresenius Kabi AG
Pfizer Inc
Bayer AG
GSK Plc
Sanofi
Novartis AG
Mylan N.V
Teva Pharmaceutical Industries Ltd
Zydus Group
Viatris Inc
Merck & Co., Inc
Recordati S.p.A
Pierre Fabre Group
AbbVie, Inc
AstraZeneca
Segment by Type
Oral
Injection
Segment by Application
Hospitals
Specialty Clinics
Other
Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Cardioselective Beta Blockers market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Cardioselective Beta Blockers, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Cardioselective Beta Blockers industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Cardioselective Beta Blockers in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Cardioselective Beta Blockers introduction, etc. Cardioselective Beta Blockers Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Cardioselective Beta Blockers market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices